Registered number
11030393
PHARMAVACCS LTD
Filleted Accounts
31 October 2025

PHARMAVACCS LTD
Registered number: | 11030393
Balance Sheet
as at 31 October 2025
Notes |  |  | 2025 |  |  | 2024
£ | £
Fixed assets
Intangible assets | 3 |  |  | 28,092 |  |  | 38,746
Current assets
Debtors | 4 |  | 111,000 |  |  | 4,637
Cash at bank and in hand |  |  | 19,453 |  |  | 21,348
|  |  | 130,453 |  |  | 25,985
Creditors: amounts falling due within one year | 5 |  | (20,967) |  |  | (14,939)
Net current assets |  |  |  | 109,486 |  |  | 11,046
Total assets less current liabilities |  |  |  | 137,578 |  |  | 49,792
Creditors: amounts falling due after more than one year | 6 |  |  | (270,000) |  |  | (220,000)
Net liabilities |  |  |  | (132,422) |  |  | (170,208)
Capital and reserves
Called up share capital |  |  |  | 1,500 |  |  | 1,500
Profit and loss account |  |  |  | (133,922) |  |  | (171,708)
Shareholders' funds |  |  |  | (132,422) |  |  | (170,208)
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
AISHA SULEMAN
Director
Approved by the board on 6 November 2025

PHARMAVACCS LTD
Notes to the Accounts
for the year ended 31 October 2025
1 | Accounting policies
| Basis of preparation
| The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
| Turnover
| Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
| Intangible fixed assets
| Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
| Tangible fixed assets
| Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
| Plant and machinery | over 10 years
| Creditors
| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2 | Employees | 2025 |  | 2024
Number | Number
| Average number of persons employed by the company | 1 |  | 2
3 | Intangible fixed assets | £
| Research & Development:
| Cost
| At 1 November 2024 | 106,536
| At 31 October 2025 | 106,536
| Amortisation
| At 1 November 2024 | 67,790
| Provided during the year | 10,654
| At 31 October 2025 | 78,444
| Net book value
| At 31 October 2025 | 28,092
| At 31 October 2024 | 38,746
| Research & Development is being written off in equal annual instalments over its estimated economic life of 10 years.
4 | Debtors | 2025 |  | 2024
£ | £
| Trade debtors | - |  | 4,637
| Other debtors (Everest Pharmacy) | 111,000 |  | -
|  |  |  |  |  | 111,000 |  | 4,637
5 | Creditors: amounts falling due within one year | 2025 |  | 2024
£ | £
| Other creditors | 20,967 |  | 14,939
6 | Creditors: amounts falling due after one year | 2025 |  | 2024
£ | £
| Other Loans | 270,000 |  | 220,000
7 | Loans from directors
| Description and conditions | B/fwd | Paid | Repaid | C/fwd
£ | £ | £ | £
| WAQQASS SHEIKH | 100,000 |  |  |  |  |  | 100,000
| DANA ABARA | - |  | 50,000 |  |  |  | 50,000
| SHATA ISMAIEL SALMAN AL JUBOORI | 100,000 |  |  |  |  |  | 100,000
| ZABIR HAKIM | 20,000 |  |  |  |  |  | 20,000
|  | 220,000 |  | 50,000 |  | - |  | 270,000
8 | Controlling party
| The company is under the ultimate control of Mr Waqqass Sheikh by virtue of him and his wife owning more than 50% of the issued share capital.
| Share capital | Nominal |  | 2025 |  | 2025 |  | 2024
value | Number | £ | £
| Allotted, called up and fully paid:
| Ordinary shares | £1 each |  |  |  | 1,500 |  | 1,000
Nominal | Number | Amount
value | £
| Shares issued during the period:
| Ordinary shares | £1 each |  | - |  | -
|  |  |  |  |  | -
| Shareholders Details | Nominal Value | Number | Amount
| Waqqass Sheikh | £1.00 |  | 450 |  | £450.00
| Rizwana Sheikh | £1.00 |  | 450 |  | £450.00
| Aisha Suleman | £1.00 |  | 100 |  | £100.00
| Shatha Ismaiel Salman al Juboori | £1.00 |  | 250 |  | £250.00
| Zabir Hakim | £1.00 |  | 250 |  | £250.00
9 | Other information
| PHARMAVACCS LTD is a private company limited by shares and incorporated in England. Its registered office is:
| 117b Withington Road
| Manchester
| M16 8EE

PHARMAVACCS LTD 11030393 false 2024-11-01 2025-10-31 2025-10-31 VT Final Accounts July 2024 AISHA SULEMAN No description of principal activity 11030393 2023-11-01 2024-10-31 11030393 core:WithinOneYear 2024-10-31 11030393 core:AfterOneYear 2024-10-31 11030393 core:ShareCapital 2024-10-31 11030393 core:RetainedEarningsAccumulatedLosses 2024-10-31 11030393 2024-11-01 2025-10-31 11030393 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 11030393 bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 11030393 bus:Director40 2024-11-01 2025-10-31 11030393 2 2024-11-01 2025-10-31 11030393 core:Goodwill 2024-11-01 2025-10-31 11030393 bus:Director1 2024-11-01 2025-10-31 11030393 bus:Director2 2024-11-01 2025-10-31 11030393 bus:Director2 1 2024-11-01 2025-10-31 11030393 bus:Director3 2024-11-01 2025-10-31 11030393 bus:Director4 2024-11-01 2025-10-31 11030393 countries:England 2024-11-01 2025-10-31 11030393 bus:FRS102 2024-11-01 2025-10-31 11030393 bus:FilletedAccounts 2024-11-01 2025-10-31 11030393 2025-10-31 11030393 core:WithinOneYear 2025-10-31 11030393 core:AfterOneYear 2025-10-31 11030393 core:ShareCapital 2025-10-31 11030393 core:RetainedEarningsAccumulatedLosses 2025-10-31 11030393 core:Goodwill 2025-10-31 11030393 bus:Director1 1 2025-10-31 11030393 bus:Director2 1 2025-10-31 11030393 bus:Director3 1 2025-10-31 11030393 2024-10-31 11030393 core:Goodwill 2024-10-31 11030393 bus:Director1 1 2024-10-31 11030393 bus:Director2 1 2024-10-31 11030393 bus:Director3 1 2024-10-31 iso4217:GBP xbrli:pure